Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab is an immunotherapeutic agent with dual specificity for CD3 and CD19 that is approved for the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL). A steroid based pre-treatment is recommended before administering blinatumomab to patients with a hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonifacio, Massimiliano, Papayannidis, Cristina, Lussana, Federico, Fracchiolla, Nicola, Annunziata, Mario, Sica, Simona, Delia, Mario, Foà, Robin, Pizzolo, Giovanni, Chiaretti, Sabina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770323/
https://www.ncbi.nlm.nih.gov/pubmed/35071008
http://dx.doi.org/10.3389/fonc.2021.804714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770323/
https://www.ncbi.nlm.nih.gov/pubmed/35071008
http://dx.doi.org/10.3389/fonc.2021.804714

Ejemplares similares